Abstract
The aims of the present study were (1) to investigate and quantify the pharmacokinetics, including inter-occasion variability and covariate relationships, of busulphan in BMT patients and (2) to develop a user-friendly initial dosing and therapeutic drug monitoring (TDM) strategy for the treatment of those patients with busulphan. The pharmacokinetics of busulphan was studied in 64 adults and 12 children who received busulphan (1 mg/kg) four times daily for 4 days. A one-compartment model with first order absorption and a lag time was sufficient in describing the concentration-time profile. Oral clearance (CL/F) was found to be correlated to weight (+1.2%/kg), ALT (−13%/μcat/l) and concomitant phenytoin treatment (+21%). CL/F and the volume of distribution (V/F) were estimated to 9.23 l/h and 39.3 l, respectively, in a typical individual. Inter-occasion variability (9.4%) in CL/F was estimated to be less than inter-individual variability (28%), a prerequisite for the value of TDM. Bayesian CL/F estimates based on three samples were in good accordance with those based on all samples. The final population model was implemented into the program Excel. The resulting flexible and easy to use dosing program might be used for both initial and, requiring only three plasma samples, maintenance dose individualization of busulphan therapy. Bone Marrow Transplantation (2001) 28, 657–664.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Copelan EA, Biggs JC, Thompson JM et al. Treatment for acute myelocytic leukemia with allogeneic bone marrow transplantation following preparation with BuCy2 Blood 1991 78: 838–843
Lu C, Braine HG, Kaizer H et al. Preliminary results of high-dose busulfan and cyclophosphamide with syngeneic or autologous bone marrow rescue Cancer Treat Rep 1984 68: 711–717
Geller RB, Saral R, Piantadosi S et al. Allogeneic bone marrow transplantation after high-dose busulfan and cyclophosphamide in patients with acute nonlymphocytic leukemia Blood 1989 73: 2209–2218
Santos GW, Tutschka PJ, Brookmeyer R et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide New Engl J Med 1983 309: 1347–1353
Slattery JT, Clift RA, Buckner CD et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation Blood 1997 89: 3055–3060
Grochow LB, Jones RJ, Brundrett RB et al. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation Cancer Chemother Pharmacol 1989 25: 55–61
Slattery JT, Sanders JE, Buckner CD et al. F Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics (published erratum appears in Bone Marrow Transplant 1996 18: 829) Bone Marrow Transplant 1995 16: 31–42
Dix SP, Wingard JR, Mullins RE et al. Association of busulfan area under the curve with veno-occlusive disease following BMT Bone Marrow Transplant 1996 17: 225–230
Hassan M, Ehrsson H, Wallin I et al. Pharmacokinetic and metabolic studies of busulfan in rat plasma and brain Eur J Drug Metab Pharmacokinet 1988 13: 301–305
Hassan M, Fasth A, Gerritsen B et al. Busulphan kinetics and limited sampling model in children with leukemia and inherited disorders Bone Marrow Transplant 1996 18: 843–850
Grochow LB, Krivit W, Whitley CB et al. Busulfan disposition in children Blood 1990 75: 1723–1727
Vassal G, Deroussent A, Challine D et al. Is 600 mg/m2 the appropriate dosage of busulfan in children undergoing bone marrow transplantation? Blood 1992 79: 2475 2479
Regazzi MB, Locatelli F, Buggia I et al. Disposition of high-dose busulfan in pediatric patients undergoing bone marrow transplantation Clin Pharmacol Ther 1993 54: 45–52
Hassan M, Oberg G, Bekassy AN et al. Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology Cancer Chemother Pharmacol 1991 28: 130–134
Vassal G, Challine D, Koscielny S et al. Chronopharmacology of high-dose busulfan in children Cancer Res 1993 53: 1534–1537
Gibbs JP, Gooley T, Corneau B et al. The impact of obesity and disease on busulfan oral clearance in adults Blood 1999 93: 4436–4440
Gibbs JP, Murray G, Risler L et al. Age-dependent tetrahydrothiophenium ion formation in young children and adults receiving high-dose busulfan Cancer Res 1997 57: 5509–5516
Grochow LB . Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens Semin Oncol 1993 20: (Suppl. 4) 18–25; quiz 26
Slattery JT, Risler LJ . Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation Ther Drug Monit 1998 20: 543–549
Chattergoon DS, Saunders EF, Klein J et al. An improved limited sampling method for individualised busulphan dosing in bone marrow transplantation in children Bone Marrow Transplant 1997 20: 347–354
Schuler U, Schroer S, Kuhnle A et al. Busulfan pharmacokinetics in bone marrow transplant patients: is drug monitoring warranted? Bone Marrow Transplant 1994 14: 759–765
Vassal G . Pharmacologically-guided dose adjustment of busulfan in high-dose chemotherapy regimens: rationale and pitfalls (review) Anticancer Res 1994 14: 2363–2370
Hassan M, Ehrsson H, Smedmyr B et al. Cerebrospinal fluid and plasma concentrations of busulfan during high-dose therapy Bone Marrow Transplant 1989 4: 113–114
Yeager AM, Wagner JE Jr, Graham ML et al. Optimization of busulfan dosage in children undergoing bone marrow transplantation: a pharmacokinetic study of dose escalation Blood 1992 80: 2425–2428
Vassal G, Gouyette A, Hartmann O et al. Pharmacokinetics of high-dose busulfan in children Cancer Chemother Pharmacol 1989 24: 386–390
Hassan M, Ehrsson H . Determination of busulfan in human plasma by gas chromatography with electron-capture detection (letter) J Chromatogr 1988 434: 330
Beal S, Sheiner L . NONMEM Users Guide. Group NP (ed) San Fransicso: University of California 1999
Karlsson MO, Sheiner LB . The importance of modeling interoccasion variability in population pharmacokinetic analyses J Pharmacokinet Biopharm 1993 21: 735–750
Jonsson EN, Karlsson MO . Xpose – an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM Comput Meth Prog Biomed 1999 58: 51–64
Hassan M, Oberg G, Ehrsson H et al. Pharmacokinetic and metabolic studies of high-dose busulphan in adults Eur J Clin Pharmacol 1989 36: 525–530
Vassal G, Fischer A, Challine D et al. Busulfan disposition below the age of three: alteration in children with lysosomal storage disease Blood 1993 82: 1030–1034
Hassan M, Ljungman P, Bolme P et al. Busulfan bioavailability Blood 1994 84: 2144–2150
Hassan M, Oberg G, Bjorkholm M et al. Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics Cancer Chemother Pharmacol 1993 33): 181–186
Sheiner LB, Beal SL . Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods J Pharmaceut Sci 1982 71: 1344–1348
Pawlowska AB, Blazar BR, Angelucci E et al. Relationship of plasma pharmacokinetics of high-dose oral busulfan to the outcome of allogeneic bone marrow transplantation in children with thalassemia Bone Marrow Transplant 1997 20: 915–920
Acknowledgements
This study was supported by the Swedish Children Cancer Society (grant 1999/033) and Swedish Cancer Society (grants 4147-B99–02XBB and 3340-B97–06XAA).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sandström, M., Karlsson, M., Ljungman, P. et al. Population pharmacokinetic analysis resulting in a tool for dose individualization of busulphan in bone marrow transplantation recipients. Bone Marrow Transplant 28, 657–664 (2001). https://doi.org/10.1038/sj.bmt.1703229
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1703229
Keywords
This article is cited by
-
Toxicological effects of fludarabine and treosulfan conditioning before allogeneic stem-cell transplantation
International Journal of Hematology (2017)
-
Pediatric Clinical Pharmacology of Voriconazole: Role of Pharmacokinetic/Pharmacodynamic Modeling in Pharmacotherapy
Clinical Pharmacokinetics (2016)
-
A Bayesian decision support tool for efficient dose individualization of warfarin in adults and children
BMC Medical Informatics and Decision Making (2015)
-
Pharmacokinetics study of once-daily intravenous busulfan in conditioning regimens for hematopoietic stem cell transplantation
International Journal of Hematology (2015)
-
Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103)
Cancer Chemotherapy and Pharmacology (2014)